Companion Animals in the Cancer Therapeutic Development Pipeline
Sunday April 07, 2019
3:00 pm
-
5:00 pm
Eastern Time (ET)
Room W205 A
BEH
DCP
Chair :
Daniel Gustafson
Colorado State University
Naturally-occurring cancers in pet animals are becoming increasingly recognized as an opportunity to advance studies in cancer drug and therapeutic development. The field of comparative oncology studies and treats canine and feline cancers both for therapeutic intent in the animal itself as well as a research tool to further understanding of human cancer and cancer therapies. This symposium will provide an introduction to the field of comparative oncology through discussions of the mutational landscape and driver mutations present in canine cancers, and how therapeutic trials in pet dogs can generate pharmacodynamic and pharmacokinetic information beneficial to the drug development process.
Speakers
Daniel Gustafson
- Colorado State University
Introduction to Comparative Oncology
Matthew Bailey
- Foundation for Biomedical Research
Perceptions of Animal Research: Challenges and Opportunities
Dawn Duval
- Colorado State University
Mutational Landscape of Spontaneous Canine Tumors and Investigation of Potential Driver Mutations and Drug Sensitivity
David Vail
- University of Wisconsin-Madison
Molecular Targets and Pharmacodynamic Driven Drug Trials in Companion Animals
Luke Wittenburg
- University of California, Davis
Pharmacokinetic Principles and Considerations for Companion Animal Drug Trials